

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Madhav S. Thakur et al.

Serial No.: 10/748,764

Art Unit:

Filed

: December 30, 2003

Examiner:

For

PHARMACEUTICAL COMPOSITION OF TOPIRAMATE

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

June 9, 2005
(Date of Deposit)

Mary A. Appollina
(Name of applicant, assignee, or Registered Representative)

/Mary A. Appollina/

(Signature)

June 9, 2005

(Date of Signature)

Commissioner for Patents P.O. Box 1450 Washington, D.C. 20231

FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sir:

This copy is supplemental to the Information Disclosure Statement mailed on June 7, 2004.

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §\$1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this

06/14/2005 RFEKADU1 00000066 100750 10748764

information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

Disclosure Statement is being filed either within three months of the filing date of the above-identified national application

In accordance with §1.97(b), since this Information

In accordance with §1.97(c), this Information
Disclosure Statement is being filed after the period set forth
in §1.97(b) above but before the mailing date of either a Final
Action under §1.113 or a Notice of Allowance under §1.311, or
an action that otherwise closes prosecution and that it is
accompanied by one of:

	Statement in Accordance with §1.97(e)
• •	(attached); or
•	Please charge Deposit Account No. 10-
	0750/ORT0957DIV/MAA the fee of $\$180.00$ as set
	forth in §1.17(p).
	In accordance with §1.97(d), this Information
Disclosure	Statement is being filed after the mailing date of
either a F	inal Action under §1.113 or a Notice of Allowance
under §1.	311 but before the payment of the Issue Fee.
Applicant(s) hereby petition(s) for consideration of this
Information	n Disclosure Statement. Included are: Statement in
Accordance	with §1.97(e) as set forth below and the fee of
<u>\$180.00</u> as	set forth in §1.17(p).
	Copies of each of the references listed on the
attached Fo	orm PTO-1449 are enclosed herewith.
	Copies of references listed on the attached Form PTO nclosed herewith EXCEPT THAT:
	In view of the voluminous nature of references
	[list as appropriate], and the likelihood that
	these references are available to the Examiner,
	copies are not enclosed herewith.
	If any of the foregoing publications are not
	available to the Examiner, Applicant will
	endeavor to supply copies at the Examiner's
	request.
	Copies of only foreign patent documents and non-
patent lite	erature are enclosed in accordance with 37 CFR 1.98

(a) (2).

<pre>There are no listed :</pre>	references which are not in the					
English language.						
☐ The relevance of those	se listed references which are					
not in the English language is as follows:						
Attached are copies	of search report(s) from					
corresponding patent application	on(s), which are listed on the					
attached Submission Under MPEP	609 D.					
Copies of the referen	nces listed on the search					
report(s) are included except i	for those previously cited in an					
IDS mailed .						
. ,						
Attached are the following	lowing non-published pending					
patent applications which may b	pe deemed relevant, which are					
listed on the attached Submissi	ion Under MPEP 609 D.					
Please charge any deficien	ncy or credit any overpayment to					
Deposit Account No. 10-0750/ORT	Γ-957DIV/MAA. This form is					
submitted in triplicate.						
	Respectfully submitted, /Mary A. Appollina/					
	Mary A. Appollina					
	Reg. No. 34,087					
•	Attorney for Applicants .					

Johnson & Johnson One Johnson & Johnson Plaza New Brunswick, NJ 08933-7003 (732) 524-3742 DATED: June 9, 2005



PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 1 of 1

a collection of information unless it displays a valid OMB control number.					
Application Number	10/748,764				
Filing Date	December 30, 2003				
First Named Inventor	Madhav S. Thakur et al.				
Group Art Unit					
Examiner Name					
Attorney Docket Number	ORT-957DIV				

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Examiner's Initials*	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published		T ²		
		JANSSEN_CILAG FARMACEUTICA, LDA, "Topamax (summary of Product Characteristics of Topiramate, approved by the Portuguese Health Authorities)", 20 ABR. 2004, Comunica No. 19, p. 11-12	XX		
		EUROPEAN COMMISSION, Directorate General III - Industry Pharmaceuticals and Cosmetics, "Guidelines - Medicinal Products for Human Use, Quality and Biotechnology", The Rules Governing Medicinal Product in European Union, Vol. 3A, pp. 143-151, 1998			
		EUROPEAN COMMISSION, Directorate General III - Industry Pharmaceuticals and Cosmetics, "Guidelines - Medicinal Products for Human Use, Quality and Biotechnology", The Rules Governing Medicinal Product in European Union, Vol. 3A, pp. 127-141, 1998			
		SIMPOSIUM TERAPEUTICO, Enciclopedia de Especialidades Farmaceuticas Portuguesas "Monography of TOPAMAX", pp. 1015-1055, 2001	XX		
		SIMPOSIUM TERAPEUTICO, Enciclopedia de Especialidades Farmaceuticas Portuguesas, "Monography of TOPAMAX", pp. 1015-1017, 2002	XX		
		SIMPOSIUM TERAPEUTICO, Enciclopedia de Especialidades Farmaceuticas Portuguesas, "Monography of TOPAMAX", pp. 974-977, 2003	XX		
		SIMPOSIUM TERAPEUTICO, Enciclopedia de Especialidades Farmaceuticas Portuguesas, "Monography of TOPAMAX", pp. 986-989, 2004	XX		

Examiner	Date	
	Date	1
Signature	Considered	
		<u> </u>

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.